Financing, Equity Capital Markets

TCR2 Therapeutics

01/21
|
$140.0 Million
Piper Sandler served as bookrunner for TCR2 Therapeutics, Inc. on a follow-on offering
Sub-Type
Follow-On Offering
Sub-Sector
Biopharma